NCT06025851 is a Phase 1 clinical trial of Anti-human CCL24 monoclonal antibody (CM-101) in Healthy, sponsored by ChemomAb Ltd..

Who is sponsoring NCT06025851?

NCT06025851 is sponsored by ChemomAb Ltd..

What drugs are being tested in NCT06025851?

Interventions in NCT06025851: Anti-human CCL24 monoclonal antibody (CM-101), Placebo.

Is NCT06025851 still recruiting?

NCT06025851 is currently completed. Last updated 11 September 2023.

Last reviewed 2023-09-11 · How we verify

NCT06025851

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects

Completed Phase 1 Last updated 11 September 2023

What this trial tests

Phase 1 trial testing Anti-human CCL24 monoclonal antibody (CM-101) in Healthy in 32 participants. Completed in 18 February 2018.

Timeline

24 July 2017

Primary endpoint
18 February 2018

18 February 2018

Quick facts

Lead sponsor	ChemomAb Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	treatment
Enrollment	32
Start date	24 July 2017
Primary completion	18 February 2018
Estimated completion	18 February 2018
Sites	1 location across Israel

Drugs / interventions tested

Anti-human CCL24 monoclonal antibody (CM-101) — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

ChemomAb Ltd. — full company profile →

Who can join

Adults 18 to 45, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is designed to investigate the safety and tolerability of CM-101 for the treatment of medical conditions involving inflammatory and fibrotic mechanisms such as non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies.
Mor A, Friedman S, Hashmueli S, Peled A, et al · · 2024 · cited 8× · PMID 38822943 · DOI 10.1007/s40264-024-01436-2
Machine Learning Identifies Key Proteins in Primary Sclerosing Cholangitis Progression and Links High CCL24 to Cirrhosis.
Snir T, Greenman R, Aricha R, Frankel M, et al · · 2024 · cited 6× · PMID 38892228 · DOI 10.3390/ijms25116042

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other ChemomAb Ltd. trials

Trials by the same sponsor.

NCT05824156 — CM-101 in NASH Patients - The SPLASH Study · Phase 2 · completed
NCT06037577 — Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Hea · Phase 1 · completed
NCT06044467 — The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalc · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06025851 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ChemomAb Ltd.
Last refreshed: 11 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06025851.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing